STTK
Shattuck Labs, Inc.NASDAQHealthcare$6.42+2.72%ClosedMarket Cap: $307.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
8.54
P/S
324.78
EV/EBITDA
-5.85
DCF Value
$0.63
FCF Yield
-12.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-177.1%
Operating Margin
-5142.7%
Net Margin
-4880.9%
ROE
-65.0%
ROA
-53.6%
ROIC
-61.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-13.3M | $-12.6M | $-0.12 | — |
| FY 2025 | $1.0M | -268.8% | $-51.5M | $-48.8M | $-0.70 | — |
| Q3 2025 | $1.0M | 100.0% | $-10.7M | $-10.1M | $-0.14 | — |
| Q2 2025 | $0.00 | -Infinity% | $-13.0M | $-12.5M | $-0.24 | — |
| Q1 2025 | $0.00 | -Infinity% | $-14.4M | $-13.7M | $-0.27 | — |
| Q4 2024 | $0.00 | NaN% | $-19.6M | $-18.7M | $-0.37 | — |
| FY 2024 | $5.7M | 100.0% | $-80.6M | $-75.4M | $-1.49 | — |
| Q3 2024 | $3.0M | 68.2% | $-17.9M | $-16.7M | $-0.33 | — |
| Q2 2024 | $1.6M | 40.2% | $-23.0M | $-21.6M | $-0.42 | — |
| Q1 2024 | $1.1M | 12.6% | $-20.0M | $-18.5M | $-0.37 | — |
| Q4 2023 | $714.0K | -37.4% | $-19.0M | $-17.7M | $-0.41 | — |
| FY 2023 | $1.7M | -143.9% | $-92.0M | $-87.3M | $-2.05 | — |